Your browser doesn't support javascript.
loading
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Arjona-Sanchez, A; Aziz, O; Passot, G; Salti, G; Esquivel, J; Van der Speeten, K; Piso, P; Nedelcut, D-S; Sommariva, A; Yonemura, Y; Turaga, K; Selvasekar, C R; Rodriguez-Ortiz, L; Sanchez-Hidalgo, J M; Casado-Adam, A; Rufian-Peña, S; Briceño, J; Glehen, O.
Afiliación
  • Arjona-Sanchez A; Unit of Surgical Oncology, University Hospital Reina Sofia, Cordoba and GE09, Group of Research in Peritoneal and Retroperitoneal Oncologic Surgery. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain. Electronic address: alvaroarjona@hotmail.com.
  • Aziz O; Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK.
  • Passot G; Department of Surgical Oncology, Hospices Civils de Lyon, France.
  • Salti G; Edward-Elmhurst Healthcare, Naperville, Illinois and University of Illinois, Chicago, USA.
  • Esquivel J; Frederick Hospital, Maryland, USA.
  • Van der Speeten K; Ziekenhuis Oost -Limburg, Genk, Belgium.
  • Piso P; Dept. for General and Visceral Surgery, Krankenhaus Barmherzige Brueder Regensburg, Germany.
  • Nedelcut DS; Dept. for General and Visceral Surgery, Krankenhaus Barmherzige Brueder Regensburg, Germany.
  • Sommariva A; Advanced Surgical Oncology Unit, Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS Padova, Italy.
  • Yonemura Y; Kishiwada Tokushukai Hospital, Japan.
  • Turaga K; University of Chicago, USA.
  • Selvasekar CR; Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK.
  • Rodriguez-Ortiz L; Unit of Surgical Oncology, University Hospital Reina Sofia, Cordoba and GE09, Group of Research in Peritoneal and Retroperitoneal Oncologic Surgery. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain.
  • Sanchez-Hidalgo JM; Unit of Surgical Oncology, University Hospital Reina Sofia, Cordoba and GE09, Group of Research in Peritoneal and Retroperitoneal Oncologic Surgery. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain.
  • Casado-Adam A; Unit of Surgical Oncology, University Hospital Reina Sofia, Cordoba and GE09, Group of Research in Peritoneal and Retroperitoneal Oncologic Surgery. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain.
  • Rufian-Peña S; Unit of Surgical Oncology, University Hospital Reina Sofia, Cordoba and GE09, Group of Research in Peritoneal and Retroperitoneal Oncologic Surgery. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain.
  • Briceño J; Unit of Surgical Oncology, University Hospital Reina Sofia, Cordoba and GE09, Group of Research in Peritoneal and Retroperitoneal Oncologic Surgery. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain.
  • Glehen O; Department of Surgical Oncology, Hospices Civils de Lyon, France.
Eur J Surg Oncol ; 47(6): 1420-1426, 2021 06.
Article en En | MEDLINE | ID: mdl-33298341
INTRODUCTION: A laparoscopic approach for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (L-CRS+HIPEC) in highly selected patients has been reported in small cohorts with a demonstrable reduction in length of stay and post-operative morbidity. This study aims to analyse individual patient data from these international centres collected through the Peritoneal Surface Oncology Group International (PSOGI) L-CRS+HIPEC registry. METHODS: An international registry was designed through a networking database (REDCAP®). All centres performing L-CRS+HIPEC were invited through PSOGI to submit data on their cases. Patient's characteristics, postoperative outcomes and survival were analysed. RESULTS: Ten international centres contributed a total of 143 L-CRS+HIPEC patients during the study period. The most frequent indication was low grade pseudomyxoma peritonei in 79/143 (55%). Other indications were benign multicyst mesothelioma in 21/143(14%) and peritoneal metastasis from colon carcinoma in 18/143 (12,5%) and ovarian carcinoma in 13/143 (9%). The median PCI was 3 (2-5). The median length of stay was 6 (5-10) days, with 30-day major morbidity rate of 8.3% and 30-day mortality rate of 0.7%. At a median follow-up of 37 (16-64) months 126/143 patients (88.2%) were free of disease. CONCLUSIONS: Analysis of these data demonstrates that L-CRS+HIPEC is a safe and feasible procedure in highly selected patients with limited peritoneal disease when performed at experienced centres. While short to midterm outcomes are encouraging in patients with less invasive histology, longer follow up is required before recommending it for patients with more aggressive cancers with peritoneal dissemination.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Seudomixoma Peritoneal / Neoplasias del Colon / Procedimientos Quirúrgicos de Citorreducción / Quimioterapia Intraperitoneal Hipertérmica / Mesotelioma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Seudomixoma Peritoneal / Neoplasias del Colon / Procedimientos Quirúrgicos de Citorreducción / Quimioterapia Intraperitoneal Hipertérmica / Mesotelioma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido